902131-33-3

Usage

Uses

Used in Pharmaceutical Industry:
2-(1H-indazol-4-yl)acetic acid is used as a building block for the synthesis of various pharmaceutical drugs due to its unique chemical structure and properties.
Used in Anticancer Applications:
In the pharmaceutical industry, 2-(1H-indazol-4-yl)acetic acid is used as a potential therapeutic agent for anticancer properties, targeting the development of drugs that can combat cancer cells.
Used in Anti-inflammatory Applications:
2-(1H-indazol-4-yl)acetic acid is utilized as a potential therapeutic agent for anti-inflammatory properties, aiming to develop drugs that can alleviate inflammation and related conditions.
Used in Antimicrobial Applications:
2-(1H-indazol-4-yl)acetic acid is also used as a potential therapeutic agent for antimicrobial properties, focusing on the development of drugs that can fight against microbial infections.
Overall, 2-(1H-indazol-4-yl)acetic acid's diverse potential applications in drug discovery and development are attributed to its unique chemical structure and properties, making it a valuable building block in the pharmaceutical industry.

Upstream product

• 186407-74-9 4-bromoindazole 
• 902131-32-2 1-acetyl-(1H-indazol-4-yl)acetonitrile 
• 23876-14-4 3-nitro-2-methylphenylacetonitrile 
• 219312-27-3 3-amino-2-methylphenylacetonitrile 

Relevant academic research and scientific papers

Synthesis of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines using Pictet-Spengler and Bischler-Napieralski cyclisation methods

In the following communication we report routes for the synthesis of a set of 8-substituted-6-phenyl-6,7,8,9-tetrahydro-3H-pyrazolo[4,3-f]isoquinolines. Pictet-Spengler and Bischler-Napieralski methodologies were employed on the relevant indazole precursors and the merits of the two cyclisation reactions for preparing these structures were assessed.

Structure-activity studies of a novel series of 5,6-fused heteroaromatic ureas as TRPV1 antagonists

Novel 5,6-fused heteroaromatic ureas were synthesized and evaluated for their activity as TRPV1 antagonists. It was found that 4-aminoindoles and indazoles are the preferential cores for the attachment of ureas. Bulky electron-withdrawing groups in the para-position of the aromatic ring of the urea substituents imparted the best in vitro potency at TRPV1. The most potent derivatives were assessed in in vivo inflammatory and neuropathic pain models. Compound 46, containing the indazole core and a 3,4-dichlorophenyl group appended to it via a urea linker, demonstrated in vivo analgesic activity upon oral administration. This derivative also showed selectivity versus other receptors in the CEREP screen and exhibited acceptable cardiovascular safety at levels exceeding the therapeutic dose.